Clinical Trial Search

Primary: Total Amount of Alcohol Consumed During the Alcohol Self Administration (ASA) Session — 4.11; 4.5 mini-drinks

Primary: Number of Subjects With Solicited Local Symptoms — 62; 68; 104; 104 Participants

Primary: 6 Months Progression-free Survival (PFS) — 0; 5 percentage of patients

Primary: Proportion of Heavy Drinking Days — 0.3072; 0.5914 proportion of days per week

Primary: Toxicity (Number of Participants With Serious Adverse Events) — 10 Participants

Primary: Estimate Efficacy of Capecitabine 7/7 in Combination With Lapatinib in Patients With HER2 Overexpressed/Amplified, Trastuzumab-refractory, Metastatic Breast Cancer as…

Primary: Part B:Change From Baseline in Proteinuria — 1.5; -0.4; 0.1; 0.7 grams per 12 hour (g/12 hour) — p=0.0449

Primary: Overall Tumor Response - Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] — 9.1 percentage of…

Primary: Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) — 0.0260; 0.0320; 0.0385; 0.0444 Litres (L)

Primary: Safety, Tolerability, and Feasibility of Combination Intra-operative 5-ALA and Gliadel Wafers Prior to Adjuvant Radiotherapy Plus Temozolomide — 62; 9; 6; 45 Participants

Primary: Change in Fugl Meyer Assessment — 9.3; 2.2; 11.9; 5.8 units on a scale

Primary: Metabolically Active Tumor Volume (MATV) Response — 20 Participants

Primary: Frequencies of Viral Shedding — 51; 22 Participants — p=0.1436

Primary: Success of DEBDOX-M1 Procedure as a Measure of Feasibility — 100 percentage of successful treatments

Primary: MADRS Total Score at Baseline and Last Acute Phase Observation — 29.4; 29.4; 29.4; 15.9 units on a scale — p=<0.01